Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Cognitive Dysfunction and Glucagon-like Peptide-1 Agonists (COGDYS-GLP1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02423824
Recruitment Status : Completed
First Posted : April 22, 2015
Last Update Posted : May 13, 2016
Sponsor:
Information provided by (Responsible Party):
University Health Network, Toronto

Results Submitted - Not Posted on ClinicalTrials.gov
Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
Recruitment Status : Completed
Actual Primary Completion Date : April 2016
Actual Study Completion Date : May 2016
Submission Cycle Results Submitted to ClinicalTrials.gov Results Returned after Quality Control Review
1 September 7, 2016
October 28, 2016
2 November 22, 2016
January 18, 2017
3 May 2, 2017
August 11, 2017
4 February 23, 2018
November 5, 2018